AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...